Published in J Affect Disord on July 17, 2009
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. Am J Psychiatry (2013) 1.50
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am (2014) 0.84
Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat (2012) 0.83
Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav (2015) 0.78
Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat (2013) 0.77
Fifty psychological and psychiatric terms to avoid: a list of inaccurate, misleading, misused, ambiguous, and logically confused words and phrases. Front Psychol (2015) 0.77
Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines. Int J Mol Sci (2016) 0.75
Generalised anxiety disorder. BMJ Clin Evid (2011) 0.75
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90
Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care (2008) 2.47
Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc (2003) 1.83
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr (2002) 1.73
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol (2003) 1.43
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection. J Clin Psychiatry (2012) 1.42
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med (2007) 1.40
Off-label use of quetiapine in New Zealand--a cause for concern? N Z Med J (2011) 1.39
Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract (2010) 1.21
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry (2008) 1.19
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol (2008) 1.16
Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol (2002) 1.13
Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol (2008) 1.00
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2002) 0.94
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther (2013) 0.93
Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol (2010) 0.93
Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med (2008) 0.92
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry (2013) 0.89
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol (2010) 0.89
A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract (2013) 0.88
Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg (2007) 0.88
Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med (2012) 0.87
Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disord (2011) 0.87
Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther (2010) 0.87
Anti-anxiety drugs reduce conflict-specific "theta"--a possible human anxiety-specific biomarker. J Affect Disord (2012) 0.86
Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry (2010) 0.86
Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res (2002) 0.86
Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry (2014) 0.86
Dose- and exposure-response to ketamine in depression. Biol Psychiatry (2011) 0.85
Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol (2009) 0.85
Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs (2012) 0.85
Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol (2011) 0.84
Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol (2012) 0.84
Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol (2006) 0.84
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis. J Affect Disord (2010) 0.84
Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry (2014) 0.84
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol (2009) 0.84
Designing a new proof-of-principle trial for treatment of partial seizures to demonstrate efficacy with minimal sample size and duration-a case study. Epilepsy Res (2013) 0.83
Time to improvement of pain and sleep quality in clinical trials of pregabalin for the treatment of fibromyalgia. Pain Med (2014) 0.83
Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet (2002) 0.83
Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat (2012) 0.83
Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. Curr Med Res Opin (2013) 0.82
The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. PLoS Negl Trop Dis (2008) 0.82
Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther (2012) 0.82
Factors associated with hospitalization of adult psychiatric patients: cluster analysis. Australas Psychiatry (2013) 0.82
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. Eur J Clin Pharmacol (2009) 0.81
Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Drug Discov Ther (2014) 0.81
Simplifying Fibromyalgia Assessment: The VASFIQ Brief Symptom Scale. Ther Adv Musculoskelet Dis (2011) 0.81
Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med (2011) 0.81
Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials. Epilepsia (2010) 0.81
Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discov Ther (2013) 0.81
Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. J Clin Pharmacol (2010) 0.81
Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. Br J Clin Pharmacol (2003) 0.81
The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry (2008) 0.80
The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull (2007) 0.80
Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol (2006) 0.80
Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin (2012) 0.80
Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol (2011) 0.80
Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. Ann Pharmacother (2005) 0.79
An open-label, add-on study of pregabalin in patients with partial seizures: a multicenter trial in Greece. Seizure (2011) 0.79
Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother (2013) 0.78
'Violence is not part of our job': a thematic analysis of psychiatric mental health nurses' experiences of patient assaults from a New Zealand perspective. Issues Ment Health Nurs (2014) 0.78
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Br J Clin Pharmacol (2009) 0.78
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract (2011) 0.78
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. Hum Psychopharmacol (2011) 0.77
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol (2011) 0.77
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. J Clin Psychiatry (2012) 0.77
Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Am J Ther (2015) 0.77
Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. JAMA Psychiatry (2013) 0.77
Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med (2013) 0.76
Sensory pain qualities in neuropathic pain. J Pain (2011) 0.76
Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med (2013) 0.76
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res (2009) 0.76
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol (2013) 0.75
Comparative efficacy of anti-manic drugs in acute mania. Lancet (2012) 0.75
Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting. PLoS Negl Trop Dis (2010) 0.75
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC). Pharmacoepidemiol Drug Saf (2011) 0.75
Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J (2010) 0.75
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2012) 0.75
Anterior Cingulate Implant for Alcohol Dependence: Case Report. Neurosurgery (2016) 0.75
Bioavailability of amlodipine besylate following oral administration as a tablet dispersed in applesauce. J Clin Pharmacol (2005) 0.75
Postgraduation retention of medical students from Otago and Auckland medical programmes. N Z Med J (2014) 0.75
Do all antidepressants cause QT prolongation--how good is the evidence? N Z Med J (2013) 0.75
Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia. Clin J Pain (2016) 0.75
Factors related to postgraduate retention of medical graduates in New Zealand. N Z Med J (2013) 0.75
Academic performance and career choices of older medical students at the University of Otago. N Z Med J (2011) 0.75
Risk management and clinical practice. N Z Med J (2015) 0.75
Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials. Curr Med Res Opin (2011) 0.75
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin (2013) 0.75